tbuckley/cabot-search huggingface dataset:
POS1251 INCIDENCE AND OUTCOMES OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION-BASED STUDY OF MORE THAN FOUR MILLION INHABITANTS IN THE LAZIO ITALIAN REGION
Authors: E. De Lorenzis, P. Parente, G. Natalello, S. Soldati, S. L. Bosello, A. Barbara, C. Sorge, S. Axelrod, L. Verardi, P. G. Cerasuolo, G. Peluso, A. Gemma, M. Davoli, D. Biliotti, V. Bruzzese, M. Goletti, M. DI Martino, M. A. D’agostino
Journal: Annals of the Rheumatic Diseases (2022)

Background The impact of the severe acute respiratory syndrome Coronavirus 2 disease (COVID-19) pandemic on people with systemic autoimmune rheumatic diseases (SARDs) remains to be fully established. It is unclear whether SARDs are an independent risk factor for COVID-19 infection and poor outcome. Objectives The aim of our study is to assess the incidence and prognosis of test-proven SARS-CoV-2 infection during the first COVID-19 wave in a large population of SARD patients of the Lazio Italian region. Methods We retrospectively evaluated in a cohort of 4.716.119 subjects aged over 18 years and affiliated to the health system of the Lazio Italian Region, the incidence and 30-day outcomes of COVID-19 infection in 40.490 SARD pts and compared to the affiliated population as incidence rate ratio adjusted for demographics and comorbidities (adjIRR). SARD diagnosis and comorbidities were derived from medical administrative records using the Chronic Related Group classification system. Data on COVID-19 infection were derived from a dedicated regional digital network. Results The risk of COVID-19 infection was increased in patients with Psoriatic Arthritis (adjIRR=1.21, 95% CI 1.10-1.33) and Undifferentiated Connective Tissue Disease (adjIRR=1.26, 95% CI 1.03-1.54). The risk of hospitalisation was higher in patients with Axial Spondylarthritis (adjIRR=2.16, 95% CI 1.45-3.22), and Systemic Vasculitis (adjIRR=1.81, 95% CI 1.07-3.06) while the risk of Intensive care unit admission was higher in Systemic Erythematous Lupus (adjIRR=3.67, 95% CI 1.52-8.83) and primary Sjögren Syndrome (adjIRR=4.13, 95% CI 1.71-9.96) patients. An increased COVID-19 mortality was reported in patients with Rheumatoid Arthritis (adjIRR=1.50, 95% CI 1.04-2.17), Systemic Erythematous Lupus (adjIRR=2.67, 95% CI 1.10-6.44), primary Sjögren Syndrome (adjIRR=2.51, 95% CI 1.12-5.62), and Scleroderma (adjIRR=4.60, 95% CI 2.06-10.29). Conclusion The incidence of severe COVID-19 is not increased in the same percentage in SARDs. Each SARD presents a peculiar pattern in terms of increased risk of COVID-19 incidence, hospitalisation, intensive care unit admission and death, that is not linked to the immunosuppressive behaviour of the disease. Disclosure of Interests None declared
AB1208 FREQUENCY OF MUSCULOSKELETAL AND OTHER EXTRA-INTESTINAL SYMPTOMS IN PATIENTS WITH CELIAC DISEASE
Authors: A. Pilipenko, V. Mazurov, I. Gaydukova
Journal: Annals of the Rheumatic Diseases (2022)

Background Celiac disease (CD) is one of the most common gastrointestinal tract diseases, in adults and children. Prevalence of CD is 1-3% [2]. The most common symptoms of CD are gastrointestinal symptoms. At the same time, celiac disease may manifest with extraintestinal symptoms, including the musculoskeletal, nervous, reproductive system, and skin, especially when it debuts at a late age [1,2]. However, data about musculoskeletal manifestations of CD are limited. Objectives To show the frequency of musculoskeletal complaints and their peculiarities in patients with CD. Methods Data from 94 patients with diagnosed by gastroenterologist celiac disease were collected with the on-lain survey. All the patients were positive in CD-related immunological and genetic tests and had biopsy established CD. Results Тhe average age of respondents is 37,52 ± 11,2 years, women 79 (84,1%), men 15 (15,9%). Among 94 respondents 0.1% do not follow a gluten-free diet, 10.6% &lt;1 year, 25.5% from 1 to 3 years, 11.7% – 4-5 years, 28.7% are on a gluten-free diet &gt;5 years, 14.9% – 10-15 years, 8.5% &gt; 15 years. Gastrointestinal symptoms have started at the age &lt; 10 years old in 59.6% of patients, in 4.2% in 11-16 years old, 13.8% at the age 17-25 years old, 12.8% at the age 26-40 years old, 9.6% had late CD onset (&gt;40 years old). Extraintestinal symptoms such as drowsiness were noted by 46.8 %, headaches by 40.4%, weakness by 59.6%, irritability by 57.4% of respondents. Lack of coordination was noticed in 18.1% of cases, dizziness in 22.3%, 57.4% have numbness, decreased sensitivity, and tingling feeling in the limbs. Joint pain had 54.3% of the patients with CD (Figure 1). Figure 1. Frequency of pain in different joints The maximal intensity of pain was noticed in the morning (8.5%) or late night (13.8%) times and fulfilled inflammatory pain criteria (ASAS). In 17% was noticed interrelation between gluten-free diet violation and the appearance of joint pain. In 26.6% was noticed signs of enthesitis. Weakness of arms was noticed by 39.4% of respondents. Non-steroidal anti-inflammatory drugs (NSAIDs) were started by 35.1% of patients, without any improvement in 66% of cases. Conclusion Patients’ surveys showed that musculoskeletal symptoms in patients with celiac disease are not a rare problem and they are comparable with the frequency of neurological symptoms. Additional research is necessary for a better understanding of the nature of musculoskeletal involvement in celiac disease. References [1]Admou, B., et al. https://doi.org/10.1155/2012/637187 . [2]Laurikka P., et al. https://doi.org/10.3390/nu10081015 Disclosure of Interests None declared
AB0435 LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT
Authors: M. De la Rubia Navarro, J. Ivorra Cortés, E. Grau García, L. Gonzalez Puig, R. Negueroles Albuixech, I. Martínez Cordellat, F. Ortiz-Sanjuán, J. E. Oller Rodríguez, S. Leal Rodriguez, C. Pávez Perales, J. J. Fragío Gil, E. Vicens Bernabeu, C. Riesco Barcena, A. V. Huaylla Quispe, L. Mas Sanchez, P. Muñoz, C. Nájera Herranz, I. Cánovas Olmos, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2022)

Background Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. Kidney affection appears in 40-50% of SLE patients and may condition the prognosis. Belimumab is a monoclonal antibody approved for SLE since 2011, but it had no lupus nephritis (NL) indication. Recently, promising results from a controlled Belimumab trial in LN were published. Objectives To analyze effectiveness of Belimumab in LN patients under follow-up by the rheumatology department of a tertiary hospital. Methods Observational, retrospective and cross-sectional study including SLE patients (SLICC/ACR 2012 criteria) treated with subcutaneous and/or intravenous Belimumab. Demographic and serological data, concomitant treatment, kidney function and urine sediment were collected. Results Sixteen patients with a median age of 47.56 (11.66) years and with 5.40 (0.55) years since Belimumab onset were included. Five patients had LN demonstrated by kidney biopsy and they were included on analysis data. In this group, median age was 39 (6.96) years, patients had 17.80 (10.38) years since SLE diagnosis and 6.6 (0,89) years since Belimumab onset. The most prevalent nephritis type was III and IV, only one patient presented V type. Regarding the treatment, every patient received antimalarial drugs (cloroquine 40%, hydroxicloroquine 60%) and mycophenolic acid. Concerning the corticosteroid therapy, all patients receive prednisone, with an average dose of 4 mg per day. The results obtained were included in the Table 1. Table 1. Onset Currently Patient NL type Proteinuria (g/24h) Creatinine (mg/dL) Glomerular filtration (ml/min) Anti-DNA C3, C4 Proteinuria (g/24h) Creatinine (mg/dL) Glomerular filtration (ml/min) Anti-DNA C3, C4 1 III 1 0.81 90 50 80, 8 0.4 0.73 89 24 80, 20 2 V 0.75 0.40 130 24 normal 0 0.49 130 43 normal 3 III 0.75 0.73 101 164 normal 0 0.80 82.9 78 normal 4 IV 0.96 1.26 55 21 normal 0.70 1.29 71 2.2 normal 5 IV 0.95 1.29 71 15 101, 10 0.17 0.88 84 85 89, 23 Conclusion Belimumab can improve LN, in terms of serological activity, kidney function and urine sediment. It could be a promising option associated to standard therapy for SLE patients with kidney affection. Disclosure of Interests None declared
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19
Authors: Dorien Feyaerts, Julien Hédou, Joshua Gillard, Han Chen, Eileen S. Tsai, Laura S. Peterson, Kazuo Ando, Monali Manohar, Evan Do, Gopal K.R. Dhondalay, Jessica Fitzpatrick, Maja Artandi, Iris Chang, Theo T. Snow, R. Sharon Chinthrajah, Christopher M. Warren, Richard Wittman, Justin G. Meyerowitz, Edward A. Ganio, Ina A. Stelzer, Xiaoyuan Han, Franck Verdonk, Dyani K. Gaudillière, Nilanjan Mukherjee, Amy S. Tsai, Kristen K. Rumer, Danielle R. Jacobsen, Zachary B. Bjornson-Hooper, Sizun Jiang, Sergio Fragoso Saavedra, Sergio Iván Valdés Ferrer, J. Daniel Kelly, David Furman, Nima Aghaeepour, Martin S. Angst, Scott D. Boyd, Benjamin A. Pinsky, Garry P. Nolan, Kari C. Nadeau, Brice Gaudillière, David R. McIlwain
Journal: Cell Reports Medicine (2022)

The biological determinants underlying the range of coronavirus 2019 (COVID-19) clinical manifestations are not fully understood. Here, over 1,400 plasma proteins and 2,600 single-cell immune features comprising cell phenotype, endogenous signaling activity, and signaling responses to inflammatory ligands are cross-sectionally assessed in peripheral blood from 97 patients with mild, moderate, and severe COVID-19 and 40 uninfected patients. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identify and independently validate a multi-variate model classifying COVID-19 severity (multi-class area under the curve [AUC]
AB0330 EXPERIENCE IN THE CURRENT PRACTICE WITH BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTICIAL LUNG DISEASE OF THE DONOSTIA UNIVERSITY HOSPITAL
Authors: J. A. Valero Jaimes, A. De Diego Sola, N. Alcorta Lorenzo, C. A. Egües Dubuc, J. M. Belzunegui Otano, E. Uriarte Isacelaya, J. J. Cancio Fanlo, L. M. Lopez Dominguez, O. Maiz-Alonso
Journal: Annals of the Rheumatic Diseases (2022)

Background Baricitinib (BARI) is a selective and reversible oral Janus kinase (JAK) inhibitor for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients with inadequate response or intolerance to one or more antirheumatic drugs disease modifiers (DMARDs). Interstitial lung disease (ILD) is a common extra-joint manifestation of RA. Symptomatic ILD occurs in 5-17% of patients with RA and influences the natural course of the disease and substantially affects morbidity and mortality, which is why we wanted to review our patients with RA and ILD who are under treatment with BARI. Objectives To assess the safety and persistence of BARI, as well as the evolution of lung function in patients with RA and ILD who are undergoing treatment with BARI, in the Rheumatology Service of the Donostia University Hospital. Methods A retrospective search was carried out of all patients undergoing BARI treatment until June 2020. The electronic medical records were reviewed. The variables collected were: sex, age, date of diagnosis of RA, history of smoking, presence of erosions, positivity for rheumatoid factor (RF), citrullinated cyclic antipeptide (anti-CCP) and previous treatments. Regarding BARI, the dose, the time since the start of treatment, related adverse effects, reason for suspension and other relevant data were collected. The quantitative variables are shown with the median and interquartile range, the qualitative variables are shown with the absolute value and its percentage. Results 17 patients with RA and ILD treated with BARI were found. Table 1 shows the clinical characteristics, Table 2 shows the treatments and Table 3 shows the respiratory function tests (RFT). All patients were positive for RF and anti-CCP, the presence of erosions was observed in 10 (59%), a history of smoking in 8 (47%), the most frequent type of ILD was Usual Interstitial Pneumopathy (UIP) 7 (41%), at the diagnosis of ILD Abatacept was the most used drug 14 (82). Before the start of BARI, the median FVC 90% (80.5-111), DLCO 69% (57-83.5) and the last control after the use of BARI the median FVC 94% (87-107), DLCO 63% (51-87), the median time of exposure to BARI was 34 months. To date, 10 (59%) patients continue with BARI and the most frequent cause of suspension was failure 2º. Conclusion A good persistence of BARI was observed (59%), it also proved to be a safe drug and kept lung function stable in these patients, so BARI can be a therapeutic option in these cases, although more studies are needed to better elucidate these findings. Figure 1. Disclosure of Interests None declared
AB0329 IS THERE A LINK BETWEEN INFLAMMATION AND AN ABNORMAL LIPOPROTEIN PROFILE IN RHEUMATOID ARTHRITIS?
Authors: B. Touil, N. Akasbi, I. EL Harch, I. El Mezouar, T. Harzy
Journal: Annals of the Rheumatic Diseases (2022)

Background The management of cardio vascular risk in rheumatoid arthritis (RA) is essential and involves the assessment of the blood lipid profile. Studies have shown that patients with active untreated RA, by the presence of a pro-inflammatory state, have a decrease of total cholesterol (TC), HDL cholesterol (HDLc) and LDL cholesterol (LDLc) [1]. The relationship between blood lipids and inflammation is the so-called `lipid paradox’ in RA [2]. Objectives To study the lipoprotein profile of patients with RA and its association with markers of inflammation and disease activity. Methods We conducted a cross sectional study among patients with established RA. We analyzed their lipoprotein profile. We further evaluated possible associations between dyslipidemia, disease activity score using the DAS28 and markers of inflammation C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)]. A disturbed lipid profile was defined by a Total Cholesterol level (TC) ≥ 5.17 mmol/L or High density lipoproteins (HDLc) ≤ 1.03 mmol/L or Low Density Lipoproteins (LDLc) ≥ 4.13 mmol/L or Triglycerides (TG) ≥ 1.69 mmol/L. Results The mean age of the 136 patients included was 55.19±11.84 years, with a female predominance (n=120). Disease duration was 16.27±11.84 years. Mean lipid concentrations were 4.73±0.95 mmol/L for TC, 1.29±0.36 mmol/L for HDLc, 2.87±0.72 mmol/L for LDLc and 1.19±0.54 mmol/L for TG. The inflammatory syndrome was present in 70% of patients. Mean ESR and CRP values were 32.81±22.19 mm at H1 and 26.17± 6.17 mg/L. A significant association was objectified between the inflammatory syndrome and low concentrations of TC (4.57 ±0.93 vs 5.09 ±1.06; p=0.010) and LDLc (2.74 ±0.69 vs 3.15 ±0.85; p=0.007). However, no relationship was found between lipid profile and disease activity. Conclusion Although there was no relation between lipids plasma levels and disease activity in our population, inflammation was linked to a decrease in CT and LDLc. Contrary to the general population, this decrease is at high cardiovascular risk joining the lipid paradox theory in RA. References [1]Myasoedova E, Kremers HM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. [2]Ann RheumDis. 2011 Mar;70(3):482-[2]: enetsanopoulou, A.I, Voulgari, P.V. and al. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int 40, 1181–1191 (2020). Disclosure of Interests None declared
AB1024 SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME
Authors: J. E. Oller Rodríguez, E. Grau García, S. Leal Rodriguez, P. Muñoz Martinez, L. Mas Sanchez, C. Riesco Barcena, A. V. Huaylla Quispe, C. Pávez Perales, M. De la Rubia Navarro, I. Martínez Cordellat, C. Nájera Herranz, R. Negueroles Albuixech, F. Ortiz-Sanjuán, E. Vicens Bernabeu, I. Cánovas Olmos, J. J. Fragío Gil, L. Gonzalez Puig, J. Ivorra Cortés, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2022)

Background Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral fracture. Despite the availability of different drugs for secondary prevention, there are few comparative studies in real clinical practice. Objectives Our aim is to evaluate the appearance of new vertebral fractures depending on the strategy chosen as secondary prevention. Methods We performed a retrospective descriptive study with patients who had suffered their first vertebral fracture between 2010 and 2018, in whom we checked the subsequent appearance of new vertebral fractures. We selected only those patients who had completed a minimum of 18 months of secondary prevention with antiresorptive drugs, or a sequential scheme (anabolic treatment followed by at least 1 year with an antiresorptive drug). Those patients who had presented new fractures in the first 6 months of treatment were excluded. Finally, we adjusted efficacy by treatment time. Results A total of 452 patients were included, out of an initial baseline pool of 1184 patients. We found female predominance (83% of the total). The mean age of the first vertebral fracture was 69.2 years, with a mean latency to fracture of 51.4 months. A new vertebral fracture happened in 4.7% of these patients. The different secondary prevention strategies were classified according to the different therapeutic options, as we can see in Table 1. Table 1. Treatment Patients (%) New fractures (%) Denosumab 205 (45.35%) 10 (4.87%) Oral bisphosphonate (alendronate, risedronate or ibandronate) 75 (16.59%) 5 (6.66%) Zoledronate 38 (8.41%) 3 (7.89%) Teriparatide followed by Denosumab 94 (20.8%) 0 (0%) Teriparatide followed by Oral bisphosphonate 36 (7.96%) 3 (8.33%) Teriparatide followed by Zoledronate 4 (0.89%) 0 (0%) No statistically significant differences between different treatments were observed, but we found a lower probability of a new fracture in patients treated with sequential treatment with teriparatide followed by denosumab. Finally, the Kapplan-Meier survival analysis showed a lower probability per year of new fractures in patients treated with teriparatide followed by denosumab, being this probability greater in patients treated with teriparatide followed by oral bisphosphonate. Conclusion A lower probability of refracture was observed in patients who received sequential treatment with teriparatide followed by denosumab. Disclosure of Interests None declared
Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism
Authors: Claude Gregoire, Lionel Spinelli, Sergio Villazala-Merino, Laurine Gil, María Pía Holgado, Myriam Moussa, Chuang Dong, Ana Zarubica, Mathieu Fallet, Jean-Marc Navarro, Bernard Malissen, Pierre Milpied, Mauro Gaya
Journal: Immunity (2022)
POS1480-HPR SCREENING WITH THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 QUESTIONNAIRE CAN REDUCE THE NUMBER OF CLINIC VISITS
Authors: J. Wiegel, B. Seppen, M. Ter Wee, M. Boers, M. Nurmohamed, W. H. Bos
Journal: Annals of the Rheumatic Diseases (2022)

Background The long-term and frequent evaluation of disease activity in patients with rheumatoid arthritis (RA) leads to a large burden of planned consultations at outpatient clinics. It might be possible to reduce that burden by prescreening to identify patients with low disease activity with the electronic Routine Assessment of Patient Index Data 3 (RAPID3), with the aim to let them skip their visits. For this purpose, accurate classification of patients in the low category with the RAPID3 is required. Objectives To evaluate the test characteristics and agreement between the Disease Activity Score 28 (DAS28) and the RAPID3 in patients with RA and low disease activity. Methods We performed a retrospective database study with clinical data collected as part of usual care from the electronic medical record at Reade Amsterdam, a secondary care center for rheumatology patients. The dataset comprised each completed RAPID3 between June 2014 and March 2021, that was followed by a DAS28 within 2 weeks in patients with RA. We dichotomized the disease activity for both the RAPID3 and DAS28 into ‘low’ and ‘high’, with cutoffs at 2.0 for RAPID3 and 3.2 for DAS28. We report test characteristics and agreement (Cohen’s kappa). Results The dataset comprises 5009 combined RAPID3 and DAS28 measurements recorded in 1681 unique RA patients. Mean age was 60 years, 76% of patients were female with a median disease duration of 4 years. Overall agreement was 0,58, ƙ was fair at 0.26, with 1426 (28%) of the RAPID3 measurements in the ‘low’ category (Table 1). Sensitivity to detect low disease activity was 0.39, specificity 0.94 and positive predicted value 0.92. Table 1. Crosstabulation of dichotomised RAPID3 and DAS28* results. DAS28 Total Low (&lt;3,2 ) High (&gt;3,2 ) RAPID3 Low (≤2,0 ) 1309 (26%) 117 (2%) 1426 (28%) High (&gt;2,1 ) 2005 (40%) 1578 (32%) 3583 (72%) Total 3314 (66%) 1695 (34%) 5009 (100%) *Disease activity score 28 (DAS28), Routine Assessment of Patient Index Data 3 (RAPID3). Conclusion With a positive predictive value of 0.92 for low disease activity, a RAPID3 score of 2.0 or lower is a good threshold to propose a postponement of the consultation and substantially reduce the clinic burden. Such a proposal is safe if the patient can overrule it. References [1]With a positive predictive value of 0.92 for low disease activity, a RAPID3 score of 2.0 or lower is a good threshold to propose a postponement of the consultation and substantially reduce the clinic burden. Such a proposal is safe if the patient can overrule it. Disclosure of Interests None declared